Cite Filings / STOK / 0000902664-26-003525

Feed Companies Filings Check

Sign in

SCHEDULE 13G/A

Statement of Beneficial Ownership

Stoke Therapeutics, Inc. Filed 2026-08-14 Acc 0000902664-26-003525

Documents 1

SCHEDULE 13G/A Statement of Beneficial Ownership , xslSCHEDULE_13G_X02/primary_doc.xml

Around this filing

2026-11-05 SCHEDULE 13G/A Statement of Beneficial Ownership
2026-08-18 4 GENERAL COUNSEL & CORP SEC sold 2,861 shares at an average $32.03 ($91,639)
2026-08-18 4 CHIEF MEDICAL OFFICER sold 4,767 shares at an average $32.03 ($152,690)
2026-08-18 4 Director sold 12,567 shares at an average $32.03 ($402,528)
2026-08-14 SCHEDULE 13G/A Statement of Beneficial Ownership
2026-08-12 SCHEDULE 13G/A Statement of Beneficial Ownership

Link to a passage

Paste a passage to link it

At least 12 characters, not counting spaces, so the link points to one passage.

External

SEC EDGAR (opens in new tab)

Loading xslSCHEDULE_13G_X02/primary_doc.xml…

Connection lost

Reconnecting…

Cite Filings isn't responding

Reconnecting…